Phaseline

Targets › FAP

FAP (Prolyl endopeptidase FAP): drug programs, companies and trials

55 programs from 46 companies in 63 trials: 37 Phase 1, 21 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Cardiovascular, Respiratory; next expected readout Dec 2026.

Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as…. (UniProt, Q12884)

Open in Phaseline: the race on FAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Medical Center Groningen68Ga-FAPI
gallium-68-labeled fibroblast activation protein inhibitor
FAPPhase 4Peyronie's DiseaseAug 2027
SOFIE[18F]FAPI-74
FAP-targeting radioactive diagnostic agent for PET imaging
FAPPhase 3Esophageal Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)Aug 2027
Cancer Institute and Hospital, Chinese Academy of Medical Sciences[68Ga]Ga-CTR-FAPI
Fibroblast activation protein (FAP) inhibitor radiopharmaceutical for PET-CT imaging
FAPPhase 3Medullary Thyroid CarcinomaSep 2028
National Heart, Lung, and Blood Institute (NHLBI)[18F]FAPI-74
Fibroblast activation protein (FAP)-targeted PET tracer
FAPPhase 3Allogeneic Stem Cell TransplantationMay 2031
John O. Prior[68Ga]Ga-FAPI-46 PET/CT
FAP-targeted PET imaging agent
FAPPhase 2Head and Neck Squamous Cell Carcinoma HNSCCDec 2026
University of Wisconsin, MadisonGa-FAPI-46
Fibroblast activation protein (FAP) inhibitor
FAPPhase 2Prostate Cancer Metastatic DiseaseJan 2027
Barbara Malene Fischer[68Ga]Ga-FAPI-46
Fibroblast activation protein (FAP) inhibitor PET tracer
FAPPhase 2Pancreatic Cancer, Adult; Malignant Melanoma Stage IVJan 2027
Maastricht University Medical Center68Ga-FAPI-46
Fibroblast activation protein (FAP) inhibitor
FAPPhase 2Breast CancerMar 2027
Aalborg University Hospital[68Ga]Ga-FAPI-46 PET/CT
Fibroblast Activation Protein (FAP) inhibitor labeled with Gallium-68 for positron emissio
FAPPhase 2Pleural MesotheliomaApr 2027
Mayo ClinicGallium Ga 68 FAPi-46
Radiopharmaceutical targeting fibroblast activation protein (FAP) on cancer-associated fib
FAPPhase 2Localized Pancreatic AdenocarcinomaJun 2027
AstraZenecaAZD2389
FAP inhibitor
FAPPhase 2Liver FibrosisJul 2027
Mara Veenstra, MD[18F]F-FAPI PET-CT
Fibroblast activation protein (FAP) inhibitor PET-CT imaging agent
FAPPhase 2CholangiocarcinomaSep 2027
University of Wisconsin, MadisonFAPI tracer
Fibroblast activation protein (FAP) inhibitor radiotracer
FAPPhase 2Fibrosis LungSep 2027
Nantes University Hospital[68Ga]Ga-FAPI-46
Fibroblast activation protein (FAP) PET tracer labeled with gallium-68
FAPPhase 2Transthyretin Cardiac AmyloidosisOct 2027
KU Leuven[18F]AlF-FAPI-74
Fibroblast activation protein (FAP) inhibitor PET tracer
FAPPhase 2Oesophageal CancerDec 2027
Peking Union Medical College Hospital[¹⁸F]AlF-NOTA-FAPI-04
Fibroblast activation protein (FAP) inhibitor PET imaging agent
FAPPhase 2Nonischemic CardiomyopathyDec 2027
Blue Earth Diagnostics[68Ga]BED003
Fibroblast activation protein (FAP) targeting PET imaging agent
FAPPhase 2Colorectal CancerFeb 2028
Universität Münster[68Ga]Ga-FAPI-46
Fibroblast activation protein (FAP) targeted positron emission tomography (PET) imaging ag
FAPPhase 2Carcinoma, Intraductal, NoninfiltratingMar 2028
University Hospital, Bordeaux68Ga-FAPI-46
Fibroblast activation protein inhibitor (FAPI) PET imaging agent
FAPPhase 2CholangiocarcinomaMar 2028
National Cancer Institute (NCI)[18F]FAPI-74
Fibroblast activation protein (FAP) inhibitor PET tracer
FAPPhase 2SarcomaJun 2028
Institut Curie68Ga-FAPI-46
Gallium-68-labeled fibroblast activation protein inhibitor used as PET radiotracer
FAPPhase 2Pancreatic Ductal Adenocarcinoma (PDAC)Aug 2029
Turku University Hospital18F-FAPI-74
fibroblast activation protein inhibitor PET tracer
FAPPhase 2Positron Emission Tomography–
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.Technetium [99mTc]-H7ND injection
Radiolabeled fibroblast activation protein (FAP) inhibitor
FAPPhase 2Solid Tumor–
Turku University Hospital[F-18]FAPI-74
Fibroblast activation protein (FAP) inhibitor PET tracer
FAPPhase 2Colon Cancer–
Xiaorong Sun[225Ac]Ac-FAPI-XT (XT117)
alpha-emitting radiopharmaceutical targeting fibroblast activation protein (FAP)
FAPPhase 1Advanced Solid TumorDec 2026
Xinlu Wang[177Lu]Lu-XT117
Lu-177 conjugate targeting FAP (fibroblast activation protein)
FAPPhase 1Advanced Solid TumorDec 2026
Ruimin Wang[177Lu]Lu-XT117
FAP-targeted radiopharmaceutical therapy (Lu-177 beta emitter conjugated to FAP-targeting
FAPPhase 1Advanced Solid TumorDec 2026
SHAOYAN LIU177Lu-CTR-FAPI
Fibroblast activation protein inhibitor-targeted radiopharmaceutical
FAPPhase 1Thyroid CancerDec 2026
First Affiliated Hospital of Fujian Medical University177Lu-JH040182
FAP-targeted radiopharmaceutical (fibroblast activation protein ligand labeled with luteti
FAPPhase 1Patients With Advanced Metastatic FAP-Positive TumorsDec 2026
Thomas HopeGallium-68 labelled (68Ga-) FAP-2286
Radiolabeled peptidomimetic that binds to Fibroblast Activation Protein (FAP) for PET imag
FAPPhase 1Solid Tumors, AdultDec 2026
Tomsk National Research Medical Center of the Russian Academy of Sciences[99mTc]Tc-HYNIC-FAPI
Fibroblast activation protein (FAP) targeting agent labeled with technetium-99m
FAPPhase 1Lung Cancer (Locally Advanced or Metastatic)Dec 2026
Peking Union Medical College Hospital[68Ga]Ga-NI-FAPI-04
Fibroblast activation protein (FAP)-targeting PET imaging agent
FAPPhase 1TumorFeb 2027
Beijing BiotechEB-MF-CAR-NK-01
Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro
MSLN, FAPPhase 1Malignant Pleural MesotheliomasMar 2027
Jonsson Comprehensive Cancer CenterGallium Ga 68 FAPi-46
FAP-targeting PET tracer
FAPPhase 1Metastatic Malignant Neoplasm in the Prostate Gland; Bladder Carcinoma; Anal CarcinomaMay 2027
Yi Tian68Ga-FXX489 (NNS309)
FAP-targeting radiotracer for PET imaging
FAPPhase 1TumorJul 2027
BioInvent InternationalBI-1607
FAP inhibitor (fibroblast activation protein inhibitor)
FAPPhase 1Melanoma MetastaticJul 2027
Abramson Cancer Center at Penn Medicine[F-18]-FAPI-74
FAP-targeted PET imaging agent; positron-emitting radiopharmaceutical for selective measur
FAPPhase 1Fibrosis (Morphologic Abnormality)Jul 2027
Avacta Life SciencesAVA6000
FAP-activated doxorubicin prodrug
FAPPhase 1Salivary Gland TumorAug 2027
Chengdu New Radiomedicine Technology177Lu-NRT6020 Injection
FAP-targeting radiopharmaceutical for radionuclide therapy
FAPPhase 1Solid Tumor MalignancyOct 2027
Chengdu New Radiomedicine Technology68Ga-NRT6020 Injection
FAP-targeting radiopharmaceutical for PET imaging
FAPPhase 1Solid Tumor MalignancyOct 2027
Oncomatryx BiopharmaOMTX705
anti-FAP antibody-drug conjugate
FAPPhase 1Advanced Solid Tumor; Pancreatic Adenocarcinoma MetastaticDec 2027
Novartis177Lu-FAP-2286
FAP-targeted peptide radioligand (177Lu-labeled)
FAPPhase 1Solid TumorDec 2027
Peking Union Medical College HospitalAl18F-NOTA-FAPI-04
18F-labeled fibroblast activation protein (FAP) inhibitor PET imaging agent
FAPPhase 1Hyperthyroidism, AutoimmuneDec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineFAP immunosuppressive CAR-DC
FAP-targeted chimeric antigen receptor dendritic cell therapy
FAPPhase 1Dilated Cardiomyopathy (DCM)Dec 2027
Ratio Therapeutics[Ac225]RTX-2358
Actinium-225 alpha emitter conjugated to FAP-targeting antibody
FAPPhase 1Advanced Soft Tissue SarcomaJan 2028
Blue Earth Diagnostics[18F]FPyQCP
Fibroblast activation protein (FAP) inhibitor positron emission tomography tracer
FAPPhase 1Colorectal CancerJan 2028
Perspective Therapeutics[203Pb]Pb-PSV359
FAP-targeting radiopharmaceutical with lead-203 for imaging
FAPPhase 1Pancreatic Ductal AdenocarcinomaJan 2028
Second Affiliated Hospital, Zhejiang University, School of Medicineautologous FAP-targeted immunosuppressive CAR-DCs (iCDC)
FAP-targeted chimeric antigen receptor dendritic cell therapy
FAPPhase 1Ischemic CardiomyopathyApr 2028
Philogen[177Lu]Lu-OncoFAP-23
Radioligand targeting fibroblast activation protein (FAP)
FAPPhase 1FAPMay 2028
Avacta Life SciencesAVA6103
FAP-activated Exatecan
FAPPhase 1Vulvar AdenocarcinomaJan 2029
Karolinska University Hospital68Ga-FAPI-46
Fibroblast Activation Protein inhibitor labeled with Gallium-68 for PET imaging
FAPPhase 1Pancreatic NeoplasmsMar 2029
Immunome177Lu-IM-3050
FAP-directed radiopharmaceutical
FAPPhase 1Solid MalignanciesDec 2029
Lantheus Medical Imaging64Cu-LNTH-1363S
FAP inhibitor radiolabeled with Copper-64 (64Cu) for PET/CT imaging
FAPPhase 1Metastatic Sarcoma–
Peking Union Medical College Hospital68Ga-FAPI
Fibroblast activation protein (FAP) inhibitor
FAPPhase 1Sjogren's Syndrome; Pulmonary Fibrosis–
National University Hospital, Singapore68Gallium-FAPI-46 PET/MRI
Fibroblast Activation Protein (FAP)-targeting PET/MRI tracer
FAPPhase 1Hepatocellular Carcinoma–

Conditions

Advanced Solid Tumor (4) Solid Tumor (2) Solid Tumor Malignancy (2) Cholangiocarcinoma (2) Pancreatic Ductal Adenocarcinoma (PDAC) (2) Tumor (2) Colorectal Cancer (2) Dilated Cardiomyopathy (DCM) (2) Solid Tumors, Adult (2) Prostate Cancer Metastatic Disease (1) Oesophageal Cancer (1) Pancreatic Neoplasms (1)

Modalities

small molecule (42), mixed (3), protein or peptide (2)

Companies

Peking Union Medical College Hospital (4) University of Wisconsin, Madison (2) Chengdu New Radiomedicine Technology (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) Avacta Life Sciences (2) Turku University Hospital (2) Blue Earth Diagnostics (2) KU Leuven (1) Karolinska University Hospital (1) Universität Münster (1) Xinlu Wang (1) Novartis (1) Jonsson Comprehensive Cancer Center (1) Mara Veenstra, MD (1) Nantes University Hospital (1) Xiaorong Sun (1) Barbara Malene Fischer (1) Ratio Therapeutics (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Mayo Clinic (1)

Related targets

MSLN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.